JRCT ID: jRCTs031180307
Registered date:15/03/2019
The effect of an anti-VEGF drug on proliferative retinopathy.
Basic Information
| Recruitment status | Complete |
|---|---|
| Health condition(s) or Problem(s) studied | Diabetic retinopathy |
| Date of first enrollment | 24/08/2018 |
| Target sample size | 30 |
| Countries of recruitment | |
| Study type | Interventional |
| Intervention(s) | Intravitreal aflibercept injection |
Outcome(s)
| Primary Outcome | Change of non-perfusion area |
|---|---|
| Secondary Outcome | Change of visual acuity, retinal thickness and neovascularization |
Key inclusion & exclusion criteria
| Age minimum | >= 20age old |
|---|---|
| Age maximum | Not applicable |
| Gender | Both |
| Include criteria | Diabetic retinopathy with macular edema and non-perfusion area |
| Exclude criteria | Posttreatment for diabetic retinopath |
Related Information
| Primary Sponsor | Kitano Shigehiko |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Bayer pharmaceutical Co., LTD. |
| Secondary ID(s) |
Contact
| Public contact | |
| Name | Shigehiko Kitano |
| Address | 8-1 Kawada-cho, Shinjuku-ku, Tokyo Tokyo Japan 162-8666 |
| Telephone | +81-3-3353-8111 |
| ge2s-ktn@asahi-net.or.jp | |
| Affiliation | Tokyo Women`s Medical University Hospital |
| Scientific contact | |
| Name | Shigehiko Kitano |
| Address | 8-1 Kawada-cho, Shinjuku-ku, Tokyo Tokyo Japan 162-8666 |
| Telephone | +81-3-3353-8111 |
| ge2s-ktn@asahi-net.or.jp | |
| Affiliation | Tokyo Women`s Medical University Hospital |